ERBB2 and breast carcinoma: Understanding of the heterogeneity of breast cancer has been deepened by the identification of different expression levels of the estrogen receptor (ER), the progesterone receptor (PR), and human epidermal growth factor receptor‐2 (Her‐2), each of which is a key biomarker used for clinical decision making.